Summary: Agilent Technologies, a major player in life sciences and chemical analysis, faces cyclical and
Summary: I reiterate a “Buy” rating on Agilent Technologies, Inc. with a one-year target price
Summary: Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors. Recent
Summary: Agilent Technologies shares looked appealing in 2023, trading at a reasonable 21 times forward
Summary: Agilent’s may be an underappreciated winner with Alnylam’s recent clinical success, as manufacturing Amvuttra
Summary: Agilent Technologies is a major player in the diagnostics and research industry, with a
Summary: Agilent has reshuffled its portfolio and increased economic returns, but growth is expected to
Summary: Agilent Technologies’ Q4 revenue was $1.69 billion, reflecting a 9.7% YoY decline, but the
Summary: Agilent is a wonderful business with a strong competitive moat, decent growth, and excellent
Summary: Agilent Technologies has a fantastic track record of strong EPS growth and outperforming capital